Provided by Tiger Trade Technology Pte. Ltd.

Iovance Biotherapeutics, Inc.

12.92
-0.0450-0.35%
Post-market: 12.88-0.0350-0.27%19:57 EDT
Volume:14.53M
Turnover:186.93M
Market Cap:5.85B
PE:-18.30
High:13.15
Open:12.52
Low:12.31
Close:12.96
52wk High:15.30
52wk Low:1.76
Shares:452.97M
Float Shares:394.00M
Volume Ratio:0.83
T/O Rate:3.69%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7058
EPS(LYR):-1.0941
ROE:-40.36%
ROA:-20.31%
PB:7.95
PE(LYR):-11.80

Loading ...

Iovance Raises FY 2026 Total Revenue Guidance to $410 Million-$420 Million

Reuters
·
Sep 29

Iovance Biotherapeutics Raises Full Year 2026 Revenue Guidance to $410 to $420 Million

THOMSON REUTERS
·
Sep 29

Iovance Grants Inducement Stock Options for 179,750 Shares at $10.02 Each

Reuters
·
Sep 19

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire
·
Sep 19

Movement Alert|Iovance Biotherapeutics, Inc. Rises 8.05% in Regular Trading, Q2 Earnings Beat and UBS Target Price Upgrade Continue to Fuel Momentum

Market Focus
·
Sep 17

Iovance Biotherapeutics Price Target Raised to $15.00/Share from $13.00 by Barclays

Dow Jones
·
Sep 17

Iovance Biotherapeutics (IOVA) Receives a Buy from Barclays

TIPRANKS
·
Sep 17

U.S. Research Roundup-Celcuity, Fluence Energy, Salesforce

Reuters
·
Sep 17

Movement Alert|Iovance Biotherapeutics, Inc. Rises 8.02% in Regular Trading, Q2 Earnings Beat and UBS Target Price Upgrade Boost Sentiment

Market Focus
·
Sep 15

Iovance Biotherapeutics to Present at Upcoming Conferences

GlobeNewswire
·
Sep 04

Iovance Biotherapeutics put volume heavy and directionally bearish

TIPRANKS
·
Sep 03

Oracle Stock Leads This High Growth Watchlist For 2026

Simply Wall St.
·
Aug 23

Iovance Grants 240,135 Inducement Stock Options Priced at $8.99 Per Share

Reuters
·
Aug 22

Iovance Biotherapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Aug 22

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire
·
Aug 22

Movement Alert|Iovance Biotherapeutics, Inc. Falls 8.06% in Regular Trading, UBS Report Flags Competitive Headwinds for Amtagvi

Market Focus
·
Aug 22

Iovance's Growth Outlook Clouded as Amtagvi Faces Competition Hurdles, UBS Says

MT Newswires Live
·
Aug 21

Iovance Biotherapeutics Price Target Raised to $7.00/Share from $4.00 by UBS

Dow Jones
·
Aug 20

Movement Alert|Iovance Biotherapeutics, Inc. Rises 9.07% in Regular Trading, Q2 Earnings Beat and UBS Price Target Raise Fuel Momentum

Market Focus
·
Aug 20

UBS Adjusts Iovance Biotherapeutics Price Target to $7 From $4, Maintains Neutral Rating

MT Newswires Live
·
Aug 20